• Je něco špatně v tomto záznamu ?

The Lymphoma-Associated Macrophage to Hodgkin-Reed-Sternberg Cell Ratio Is a Poor Prognostic Factor in Classic Hodgkin Lymphoma Patients

V. Procházka, T. Papajík, T. Dýšková, M. Dihel, S. Brychtová, Z. Prouzová, E. Kriegová, M. Lukášová, V. Hanáčková,

. 2019 ; 19 (10) : e573-e580. [pub] 20190705

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025601

BACKGROUND: Despite the relatively high rate of curability, approximately 20% to 30% of patients with classic Hodgkin lymphoma relapse. Hodgkin-Reed-Sternberg (HRS) cells:lymphoma-associated macrophages (LAMs) cross talk promotes tumor growth and resistance to therapy. The aim of the study was to assess the prognostic role of the LAM to HRS ratio (LHR) in lymph node biopsies using a novel automated system for scanning large sample areas. PATIENTS AND METHODS: High-quality tissue samples obtained from 71 patients and stained with anti-CD30 and anti-CD68 were analyzed using the TissueFAXS (TissueGnostics). RESULTS: A high LHR was associated with inferior 5-year progression-free survival (PFS; 50.0% vs. 79.3%; P = .032) and overall survival (OS; 65.4% vs. 92.3%; P = .012). Multivariate Cox regression identified the high LHR as an unfavorable prognostic factor for PFS (hazard ratio [HR], 3.07; P = .029) and OS (HR, 4.56; P = .025). CONCLUSION: A high LHR at diagnosis is associated with a higher risk of lymphoma progression or death. Automated image analysis is a new tool that can overcome technical limitations of by microarray samples in lymphomas with high intratumor heterogeneity.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025601
003      
CZ-PrNML
005      
20201222155309.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clml.2019.07.001 $2 doi
035    __
$a (PubMed)31377208
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Procházka, Vít $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic. Electronic address: vit.prochazka@fnol.cz.
245    14
$a The Lymphoma-Associated Macrophage to Hodgkin-Reed-Sternberg Cell Ratio Is a Poor Prognostic Factor in Classic Hodgkin Lymphoma Patients / $c V. Procházka, T. Papajík, T. Dýšková, M. Dihel, S. Brychtová, Z. Prouzová, E. Kriegová, M. Lukášová, V. Hanáčková,
520    9_
$a BACKGROUND: Despite the relatively high rate of curability, approximately 20% to 30% of patients with classic Hodgkin lymphoma relapse. Hodgkin-Reed-Sternberg (HRS) cells:lymphoma-associated macrophages (LAMs) cross talk promotes tumor growth and resistance to therapy. The aim of the study was to assess the prognostic role of the LAM to HRS ratio (LHR) in lymph node biopsies using a novel automated system for scanning large sample areas. PATIENTS AND METHODS: High-quality tissue samples obtained from 71 patients and stained with anti-CD30 and anti-CD68 were analyzed using the TissueFAXS (TissueGnostics). RESULTS: A high LHR was associated with inferior 5-year progression-free survival (PFS; 50.0% vs. 79.3%; P = .032) and overall survival (OS; 65.4% vs. 92.3%; P = .012). Multivariate Cox regression identified the high LHR as an unfavorable prognostic factor for PFS (hazard ratio [HR], 3.07; P = .029) and OS (HR, 4.56; P = .025). CONCLUSION: A high LHR at diagnosis is associated with a higher risk of lymphoma progression or death. Automated image analysis is a new tool that can overcome technical limitations of by microarray samples in lymphomas with high intratumor heterogeneity.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a CD antigeny $x metabolismus $7 D015703
650    _2
$a antigeny diferenciační myelomonocytární $x metabolismus $7 D015214
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a biopsie $x metody $7 D001706
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a Hodgkinova nemoc $x farmakoterapie $x metabolismus $x patologie $7 D006689
650    _2
$a lidé $7 D006801
650    _2
$a antigen Ki-1 $x metabolismus $7 D017730
650    _2
$a lymfatické uzliny $x patologie $7 D008198
650    _2
$a makrofágy $x patologie $7 D008264
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a lokální recidiva nádoru $7 D009364
650    _2
$a prognóza $7 D011379
650    _2
$a buňky Reedové-Sternberga $x patologie $7 D016539
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Papajík, Tomáš $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic.
700    1_
$a Dýšková, Tereza $u Department of Immunology (OLGEN), Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic.
700    1_
$a Dihel, Martin $u Department of Immunology (OLGEN), Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic.
700    1_
$a Brychtová, Světlana $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic.
700    1_
$a Prouzová, Zuzana $u Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Kriegová, Eva $u Department of Immunology (OLGEN), Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic.
700    1_
$a Lukášová, Marie $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic.
700    1_
$a Hanáčková, Veronika $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic.
773    0_
$w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 19, č. 10 (2019), s. e573-e580
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31377208 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155305 $b ABA008
999    __
$a ok $b bmc $g 1599746 $s 1116287
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 19 $c 10 $d e573-e580 $e 20190705 $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...